Press ReleaseRevises 2019 Full Year Revenue Guidance
SAN DIEGO--(BUSINESS WIRE)--Jul. 11, 2019--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance.
Subject to quarter-end closing adjustments, the Company expects to report second quarter revenue of approximately $835 million, compared to $830 million in the second quarter of 2018.
The Company’s second quarter results were impacted by the following:
Approximately $30 million lower revenue than expected associated with population genomics [REMOVIDO]s, including a sizeable sequencing systems and consumables purchase that did not close as expected in the second half of June, which is now expected to close later in 2019.
Approximately $10 million lower revenue than expected associated with ongoing weakness in the direct-to-consumer (DTC) market, primarily impacting array services.
Approximately $10 million lower revenue than expected associated with Illumina’s non-high-throughput sequencing systems and consumables. While lighter than anticipated, NextSeq system and consumables shipments grew both sequentially and year-over-year, and average pull-through per NextSeq system was within Illumina’s target range.
NovaSeq consumable volume growth of 40% sequentially, and more than 100% year-over-year, with particularly strong growth in the S4 and S1 flow cells. NovaSeq system shipments were ahead of expectations in the second quarter, excluding the multi-system population genomics transaction referenced above.
“We are obviously disappointed with our second quarter financial results. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business,” said Francis deSouza, President and CEO. “Despite our shortfall this quarter, we remain as enthusiastic about the long-term growth prospects for our markets as we have ever been, and are committed to setting the industry’s bar for consistency and execution in the dynamic and rapidly growing world of genomics.”
